Compare Ascendis Pharma A/S (ASND) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.8. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| ASND | MSTU | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $106.80 |
52-Week Low | $163.32 | $1.46 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MSTU trades at $1.875, up 1.35% today, but the technical outlook is bearish with moving averages signaling strong selling pressure. The ETF, which aims for 2x daily returns of MicroStrategy (MSTR), has experienced extreme volatility and significant losses historically. Recent news highlights its high-risk nature, with articles noting substantial declines over the past year.
The outlook remains highly speculative due to leveraged exposure to MSTR's volatility. Key risks include daily rebalancing effects amplifying losses, dependence on MSTR's performance, and overall market sentiment toward Bitcoin-linked assets. This ETF is suitable only for investors comfortable with extreme risk and short-term trading.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
